Rein Therapeutics Files 2024 10-K, Cites Name Change & Financials
Ticker: RNTX · Form: 10-K · Filed: Apr 7, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 10-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, name-change, financials, pharmaceutical
TL;DR
Rein Therapeutics (RNTX) filed its 2024 10-K. Name changed from Aileron. Financials and warrants detailed.
AI Summary
Rein Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly Aileron Therapeutics, Inc., is involved in pharmaceutical preparations. Key events mentioned include a name change on March 29, 2024, and various agreements and financial instruments such as warrants and preferred stock, with specific dates like May 5, 2024, and May 2024. The filing also references financial metrics and risk inputs as of December 31, 2024.
Why It Matters
This filing provides a comprehensive overview of Rein Therapeutics' financial health and operational status for 2024, including significant corporate actions like its name change, which is crucial for investors to assess the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Rein Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 20241231 — Fiscal Year End (The reporting period for the 10-K filing.)
- 20250407 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Filer of the 10-K
- Aileron Therapeutics, Inc. (company) — Former name of Rein Therapeutics, Inc.
- 20241231 (date) — Fiscal year end
- 20250407 (date) — Filing date
- Marcum LLP (company) — Auditor
- 20240329 (date) — Date of name change
- rntx:LungAcquisitionMember (other) — Specific company event/disclosure
- us-gaap:WarrantMember (financial_instrument) — Financial instrument mentioned
- rntx:SeriesXPreferredStockMember (financial_instrument) — Specific preferred stock series
- rntx:HarvardAndDanafarberAgreementMember (agreement) — Specific agreement
FAQ
What was the primary reason for Rein Therapeutics, Inc. changing its name from Aileron Therapeutics, Inc. on March 29, 2024?
The provided text indicates the name change occurred on March 29, 2024, but does not specify the reason.
What is the significance of 'rntx:LungAcquisitionMember' mentioned in the filing?
The filing mentions 'rntx:LungAcquisitionMember' in relation to the period 2023-01-01 to 2023-12-31, suggesting it's a specific event or disclosure category for that fiscal year.
What financial instruments, besides common stock, are explicitly referenced in the filing for the fiscal year 2024?
The filing explicitly references 'us-gaap:WarrantMember' and 'rntx:SeriesXPreferredStockMember' for the fiscal year 2024.
What is the business address of Rein Therapeutics, Inc. as listed in the 10-K?
The business address is 12407 N. MOPAC EXPY., SUITE 250 #390, AUSTIN, TX 78758.
What specific agreement involving Harvard and Dana-Farber is mentioned in the context of the 2023 fiscal year?
The filing mentions 'rntx:HarvardAndDanafarberAgreementMember' in conjunction with 'us-gaap:LicenseMember' for the period 2023-01-01 to 2023-12-31.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 7, 2025 regarding Rein Therapeutics, Inc. (RNTX).